American College of Chest Physicians Disagrees with FDA Decision to Approve Over-the-Counter Epinephrine for the Treatment of Asthma

November 9, 2018

Glenview, IL – The American College of Chest Physicians (CHEST) is disappointed with the FDA’s decision to approve over-the counter epinephrine (Primatene® Mist HFA) for the treatment of asthma. CHEST is a nonprofit organization dedicated to advancing best patient outcomes. Our membership of over 19,000 members from around the world provide patient care in pulmonary, critical care, and sleep medicine.

Asthma is a serious and chronic condition with associated high healthcare burden. Care for ALL patients with asthma should be under the guidance of a health care provider. Majority of asthma patients require treatment with a controller medication, which is only available by prescription. Frequent rescue inhaler use has been associated with increased morbidity and mortality. Over the counter availability of a reliever medication like Primatene® Mist can endanger patient’s wellbeing by providing temporary relief in symptoms and resulting in delay in seeking medical care.

About the American College of Chest Physicians®
CHEST is the global leader in prevention, diagnosis, and treatment of chest diseases. Its mission is to champion advanced clinical practice, education, communication, and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care, and sleep medicine. For information about the American College of Chest Physicians, and its flagship journal CHEST®, visit chestnet.org.

Copyright 2019 © American College of Chest Physicians®

Printed from: http://www.chestnet.org/News/Press-Releases/2018/11/OTC-Epinephrine